Thymalin

Thymalin is a heterogeneous polypeptide complex derived from calf thymus gland tissue, developed within the Russian bioregulator research tradition pioneered by Vladimir Khavinson and colleagues. Unlike thymosin alpha-1 (a defined single peptide) or thymulin (a nonapeptide secreted by thymic epithelial cells), thymalin is an incompletely characterised mixture of thymic peptides standardised by biological activity rather than chemical identity.

Russian and Eastern European clinical practice has applied thymalin as an immune restoration therapy in elderly patients with immune senescence (age-related immune decline), patients recovering from serious illness or surgery, and individuals with chronic immune suppression. The proposed mechanism involves thymus-derived signalling peptides restoring T-cell maturation and differentiation capacity that declines with age as thymic involution progresses.

Clinical data from Soviet and Russian studies is largely unavailable in the Western scientific literature due to language and access barriers. The evidence base accessible to Western researchers is limited, and thymalin sits at the intersection of bioregulator research and geroprotective medicine. Its evidence classification is anecdotal by conventional standards.